Close Menu
Home › Myriad Genetics, AstraZeneca, Merck Expand BRCA CDx Collaboration

Myriad Genetics, AstraZeneca, Merck Expand BRCA CDx Collaboration

Apr 04, 2019

NEW YORK (GenomeWeb) – Myriad Genetics announced today it has expanded its collaboration with AstraZeneca and Merck to use its BRACAnalysis CDx test to identify men with metastatic, castrate-resistant prostate cancer (mCRPC) and germline BRCA mutations who are likely to respond to olaparip (Lynparza).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Jul
23
Featured Webinar

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
30
Featured Webinar

Single-Cell Sequencing Reveals Clonal Heterogeneity in Acute Lymphoblastic Leukemia

Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

What's Popular?

In Cancer

  1. Liquid Biopsy Assay From MSKCC Approved by New York State

  2. AmoyDx, Premia Partner With Loxo on Genetic Testing for Cancer Therapy

  3. Liquid Biopsy Monitoring, Surveillance Efforts Accelerate Across Cancer Types and Technologies

    Premium

  4. Next-Generation Sequencing of Pediatric Cancer Patients Could Transform Treatment Paradigms

    Premium

  5. IsoPlexis Wins $4M SBIR Grant From NCI

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.